Dr. Andrew Inltekofer

Title of Grant:       Elucidating and targeting IDH2 mutations in T cell lymphoma

 Description: Drugs that target mutant forms of the metabolic enzyme isocitrate dehydrogenase 2 (IDH2) are a promising appraoch to treat some cancers. The proposed research will uncover how mutant IDH2 causes T cell lymphoma and determine whether inhibiting mutant IDH2 offers an effective way to treat this type of blood cancer.